A Study to Investigate Weight Management with Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults with Obesity or Overweight

Inclusion Criteria:

• Have a BMI of

• ≥30 kilograms per square meter (kg/m2) or

• ≥27 kg/m2 and <30 kg/m2, with at least one of the following weight-relatedcomorbidities:

• Hypertension

• Dyslipidemia

• Cardiovascular disease

• Obstructive sleep apnea

• Have had a stable body weight for the 3 months prior to randomization (<5% bodyweight gain and/or loss)

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity

• Have at least one laboratory value suggestive of diabetes during screening

• Use of metformin, or any other glucose-lowering medications

• Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form ofdiabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, orhistory of ketoacidosis or hyperosmolar coma

• Have poorly controlled hypertension

• Have any of the following cardiovascular conditions within 3 months prior toscreening:

• acute myocardial infarction

• cerebrovascular accident (stroke)

• unstable angina, or

• hospitalization due to congestive heart failure

• Have ongoing or a history of frequent intermittent or chronic tachyarrhythmiasyndromes

• Have ongoing or a history of bradyarrhythmias other than sinus bradycardia

• Have a history of New York Heart Association (NYHA) Functional Classification III orIV congestive heart failure

• Have a history of symptomatic gallbladder disease within the past 2 years

• Have signs and symptoms of any liver disease

• Have a disease or condition known to cause gastrointestinal malabsorption or a knownclinically significant gastric emptying abnormality

• Have a history of acute or chronic pancreatitis

• Have renal impairment, measured as estimated glomerular filtration rate <30mL/minute/1.73 m2

• Currently taking or have taken medications that may cause significant weight gain orpromote weight loss within 3 months prior to screening